医学
呼出气一氧化氮
骨膜炎
哮喘
生物标志物
炎症
免疫学
重症监护医学
支气管收缩
生物化学
生物
细胞生物学
化学
细胞外基质
作者
Ida Mogensen,Anna James,Andreï Malinovschi
出处
期刊:Current Opinion in Allergy and Clinical Immunology
[Ovid Technologies (Wolters Kluwer)]
日期:2019-10-25
卷期号:20 (1): 71-79
被引量:25
标识
DOI:10.1097/aci.0000000000000599
摘要
Purpose of review Finding suitable biomarkers to phenotype asthma, identify individuals at risk of worsening and guide treatment is highly prioritized in asthma research. We aimed to provide an analysis of currently used and upcoming biomarkers, focusing on developments published in the past 2 years. Recent findings Type 2 inflammation is the most studied asthma mechanism with the most biomarkers in the pipeline. Blood eosinophils and fractional exhaled nitric oxide (FeNO) are those most used clinically. Recent developments include their ability to identify individuals at higher risk of exacerbations, faster decline in lung function and more likely to benefit from anti-IL-5 and anti-IL-4/-13 treatment. Certain patterns of urinary eicosanoid excretion also relate to type 2 inflammation. Results of recent trials investigating the use of serum periostin or dipeptidyl peptidase-4 to guide anti-IL-13 therapy were somewhat disappointing. Less is known about non-type 2 inflammation but blood neutrophils and YKL-40 may be higher in patients with evidence of non-type 2 asthma. Volatile organic compounds show promise in their ability to distinguish both eosinophilic and neutrophilic asthma. Summary The ultimate panel of biomarkers for identification of activated inflammatory pathways and treatment strategies in asthma patients still lies in the future, particularly for non-type 2 asthma, but potential candidates are available.
科研通智能强力驱动
Strongly Powered by AbleSci AI